KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $29.17 Consensus Price Target from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $29.1667.

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Citizens Jmp lowered their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Finally, HC Wainwright lifted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th.

KalVista Pharmaceuticals Trading Down 2.5%

Shares of KALV stock opened at $15.12 on Tuesday. KalVista Pharmaceuticals has a 12-month low of $8.99 and a 12-month high of $19.00. The company has a market capitalization of $764.32 million, a PE ratio of -3.83 and a beta of -0.19. The firm has a 50 day moving average price of $15.66 and a two-hundred day moving average price of $13.81. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The firm had revenue of $13.69 million for the quarter, compared to the consensus estimate of $6.03 million. As a group, analysts predict that KalVista Pharmaceuticals will post -3.56 earnings per share for the current year.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CFO Brian Piekos sold 4,471 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the transaction, the chief financial officer owned 10,529 shares in the company, valued at approximately $141,615.05. This trade represents a 29.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul K. Audhya sold 5,296 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider directly owned 131,831 shares of the company’s stock, valued at approximately $1,773,126.95. This trade represents a 3.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 28,001 shares of company stock valued at $398,933 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of large investors have recently bought and sold shares of KALV. Emerald Advisers LLC boosted its stake in KalVista Pharmaceuticals by 30.2% in the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after buying an additional 313,205 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its holdings in shares of KalVista Pharmaceuticals by 26.4% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock worth $8,693,000 after acquiring an additional 160,759 shares during the last quarter. Stonepine Capital Management LLC boosted its stake in shares of KalVista Pharmaceuticals by 364.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $1,130,000 after purchasing an additional 78,450 shares in the last quarter. F m Investments LLC boosted its stake in shares of KalVista Pharmaceuticals by 263.8% in the 2nd quarter. F m Investments LLC now owns 182,262 shares of the specialty pharmaceutical company’s stock valued at $2,060,000 after purchasing an additional 132,165 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of KalVista Pharmaceuticals during the 2nd quarter valued at approximately $1,747,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.